These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 21674642)

  • 1. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease.
    Calì T; Ottolini D; Brini M
    Biofactors; 2011; 37(3):228-40. PubMed ID: 21674642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson's disease.
    Arduíno DM; Esteves AR; Cardoso SM; Oliveira CR
    Neurochem Int; 2009 Sep; 55(5):341-8. PubMed ID: 19375464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
    Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of Parkinson disease.
    Eriksen JL; Wszolek Z; Petrucelli L
    Arch Neurol; 2005 Mar; 62(3):353-7. PubMed ID: 15767499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging (and converging) pathways in Parkinson's disease: keeping mitochondrial wellness.
    Cieri D; Brini M; Calì T
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1020-1030. PubMed ID: 27581196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
    Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
    Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG
    Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.
    McNaught KS; Olanow CW
    Neurobiol Aging; 2006 Apr; 27(4):530-45. PubMed ID: 16207501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease.
    Wang HQ; Takahashi R
    Antioxid Redox Signal; 2007 May; 9(5):553-61. PubMed ID: 17465880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current perspective of mitochondrial biology in Parkinson's disease.
    Ammal Kaidery N; Thomas B
    Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.